NANO-CARE-DEUTSCHLAND-AG
Nanotechnology company Nano-Care Deutschland AG was honored on 28.05.2019 with the German Innovation Award 2019 at the German Museum of Technology in Berlin for its new innovation in the field of antimicrobial coatings to prevent life-threatening infections caused by microorganisms such as methicillin-resistant Staphylococcus aureus (MRSA "staph infections").
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190529005812/en/
The new technology - "Liquid Guard" – which will be launched worldwide, including in the United States and China, will protect surfaces from microbial growth 24 hours a day against microorganisms including Staphylococci, which can no longer be controlled by common antibiotics.
Whilst most EPA or BPR approved products are limited in their duration of efficacy, the new development provides durable protection against e.g. skin and staph infections, attacks to immune systems and acts as a long-term disease control.
Besides skin-to-skin contact risks, which can be controlled by hand sanitizers, smear infections from personal items or surgical wounds (invasive MRSA infections) are one of the most common causes of infection, because they can carry MRSA through direct contact.
"Although short-term disinfectants are non-toxic, they only have temporary effect. Microbial growth starts immediately after application of such antimicrobial sprays, as their durability against odor-causing bacteria, and mold growth (mold control) leaves a lot to be desired. Most customer reviews show limited durability of antimicrobial products", says Oliver Sonntag, CEO of Nano-Care Deutschland AG. "We are proud to be honored with this award for our new innovation for public health, which leaves a permanent antimicrobial coating on surfaces and acts against MRSA bacteria", says Dr. Fabienne Hennessen, microbiologist of Nano-Care Deutschland AG.
The Davos World Economic Forum, consider the growing number of antibiotic resistant bacteria to be one of the 10 greatest threats to global health. The likelihood that an infected person will die has increased alongside incidents of MRSA infections in recent years.
In healthcare facilities such as hospitals or nursing homes, where poor hand-washing can result in the spread of MRSA, risks from other infections like bacterial gastrointestinal diseases can be kept from healthy people in healthcare settings. Nano-Care has signed a contract for the European market with a healthcare provider for exclusive distribution in this sector.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005812/en/
Contact:
Oliver Sonntag CEO Nano-Care Deutschland AG Telefon: +49 6838 9749140 info@nano-care.de www.nano-care.com www.liquidguard.de
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom